Bristol Myers Squibb Reports Phase 2b Data for Tisagenlecleucel in Atrial fibrillation

Bristol Myers Squibb today announced Phase 2b results for tisagenlecleucel in patients with atrial fibrillation. The study demonstrated that tisagenlecleucel improves quality of life compared to standard of care or placebo. These results provide important insights into the treatment of atrial fibrillation and support the continued development of tisagenlecleucel in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.